Asia-Pacific Graves’ diseases market is growing at a CAGR of around 5.5% during the forecast period. The region has a potential market for the Grave’s disease market due to the increasing prevalence of diabetes in the emerging economies of the region, especially in China. Diabetic patients, in particular, type-1 diabetic patients, are more prone to develop Grave’s disease. Furthermore, emerging healthcare infrastructure coupled with increasing disposable income is also expected to drive the adoption of treatment of Grave’s disease, in turn affecting the Asia-Pacific Graves’ disease market growth.
According to IDF, in 2017, there were around 1.1, 3.6, and 10.3 million numbers of people, who were diagnosed with diabetes, in Australia, South Korea, and Indonesia respectively. These figures are expected to reach around 1.5, 4.6, and 16.2 million, by 2040, in Australia, South Korea, and Indonesia respectively. The prevalence rate of diabetes in Australia and Indonesia are around 5.1% and 6.3% which increases the probability of person acquiring Grave’s disease and thus, promises the significant market for the Grave’s disease in the region. Whereas, China accounts for nearly 121 million individuals live with diabetes and around 74 million people living with diabetes in India. The development of personalized medicines such as the introduction of traditional Chinese medicine (TCM) further propels the growth of the Asia-Pacific Graves’ disease market during the forecast period.
Despite an economic slowdown in several countries of the region such as India, the increasing public healthcare programs including the increasing private wealth are further expected to propel the healthcare spending of Asia-Pacific by an annual average of 6.6% from 2015 to 2019. Asia-Pacific is growing at a modest rate in the market due to various factors such as rising healthcare spending, improving infrastructure, and rising standards of living. China, India, Japan, Australia, Korea, and Taiwan are the key countries growing at a significant rate in the Asia-Pacific Graves’ diseases market.
To Request a Sample of our Report on Asia-Pacific Graves’ disease Market: https://www.omrglobal.com/request-sample/asia-pacific-graves-disease-market
Asia-Pacific Graves’ disease Market Segmentation
By Diagnosis
- Ultrasound
- Imaging Tests
- Radioactive Iodine Uptake
- Blood Sample
By Treatment
- Anti- Thyroid Medication
- Radioactive Iodine Therapy
- Surgery
A full Report Asia-Pacific Graves’ disease Market is Available @ https://www.omrglobal.com/industry-reports/asia-pacific-graves-disease-market
Regional Analysis
- China
- India
- Japan
Rest of Asia-Pacific
Company Profiles
- Abbott Laboratories Inc.
- Allergan PLC
- Eli Lilly and Co.
- GlaxoSmithKline PLC
- Johnson & Johnson
- Macleods Pharmaceuticals Ltd.
- Merck & Co. Inc.
- Mylan NV
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
